Piramal Pharma Ltd
Piramal Pharma Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY27 revenue growth expected in the early to mid-teens percentage range across all businesses. For FY27, Piramal Pharma expects early to mid-teens revenue growth across all businesses.
From Piramal Pharma Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY27 revenue growth expected in the early to mid-teens percentage range across all businesses.
- CDMO business growth anticipated to be healthy due to improved biotech funding, increased RFPs, higher win rates, and a strong pipeline of RFPs at overseas sites.
- CDMO revenue will remain back-weighted to the second half, especially Q4, due to client order timings.
- On-patent commercial manufacturing revenue grew nearly 50% from the prior year, with 15–16 products supplied; expected continued growth with new product launches.
- ADC (Antibody-Drug Conjugates) segment poised to be a meaningful growth driver in FY27-FY28 and beyond with new customers added.
- Consumer Health Care business grew 17% in FY26 and expects continued broad-based growth with premiumization and strategic launches.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Piramal Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The Lexington expansion is ongoing with expected completion in the latter half of calendar year 2027.
- The Riverview expansion is largely complete and already serving clients.
- Capex for FY27 is projected at INR 120 million to INR 135 million, largely towards the Lexington expansion.
- No new significant capex plans were indicated beyond these projects, suggesting a period of consolidation.
- Customer-funded capex related to a specific suite is complete; no further spend planned there.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Piramal Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Piramal Pharma is seeing a strong pipeline of Requests for Proposals (RFPs) at overseas sites, which, if converted, will help scale revenues and improve operating leverage.
- The company has improved RFP-to-order conversion rates, especially with new customers.
- A healthy order book for FY27 and beyond is expected, which is crucial for medium-term growth.
- They are working on over 155 molecules in development, with 25 in Phase III, representing future on-patent commercial manufacturing opportunities.
2 more points management made on order book & pipeline
Piramal Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.8K Cr, net loss ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Piramal Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Piramal Pharma Ltd Q4 FY26 results?
FY27 revenue growth expected in the early to mid-teens percentage range across all businesses. For FY27, Piramal Pharma expects early to mid-teens revenue growth across all businesses.
What is Piramal Pharma Ltd share price analysis?
Piramal Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹27,530 Cr. Investors should review the full earnings analysis for detailed insights.
Is Piramal Pharma Ltd planning capital expenditure?
The Lexington expansion is ongoing with expected completion in the latter half of calendar year 2027.
Keep Piramal Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.